Patent application number | Description | Published |
20090137782 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 05-28-2009 |
20110076232 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 03-31-2011 |
20120183471 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 07-19-2012 |
Patent application number | Description | Published |
20090208932 | Methods Of Detecting An Analyte In A Sample - The invention relates to methods for detecting an analyte in a sample. The methods rely on the activity of polymerases upon polynucleotide substrates which are linked to a molecule, for example an antibody, which binds the analyte. Activity of the polymerases can be detected by the incorporation of suitably labelled nucleotides, and/or the incorporation of hapten conjugated nucleotides capable of binding a suitably labelled ligand of the hapten. | 08-20-2009 |
20090220510 | Specific binding proteins and uses thereof - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 09-03-2009 |
20110293511 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 12-01-2011 |
20110313230 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 12-22-2011 |
20130266573 | Specific binding proteins and uses thereof - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 10-10-2013 |
20140255410 | Specific binding proteins and uses thereof - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 09-11-2014 |
Patent application number | Description | Published |
20100261162 | Methods of assaying for telomerase activity and compositions related to same - The present invention relates generally to the field of diagnostic and prognostic assays such as diagnostic assays for conditions associated with telomerase activity. More particularly, the present invention provides an assay for measuring telomerase activity as an indicator of cancer, an inflammatory disorder and/or a condition involving embryogenesis and/or requiring stem cell proliferation and agents and kits useful for same. Automated and partially automated assays permitting high throughput screening also form part of the present invention. The subject invention further contemplates methods of treatment using agents identified by the subject assay or where treatment protocols are monitored by the assay. | 10-14-2010 |
20130345322 | DIAGNOSTIC FOR COLORECTAL CANCER - The present invention provides a method for diagnosing or detecting colorectal cancer in a subject, the method comprising determining the presence and/or level of biomarkers selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1β, TGFβ1, and TIMP-1. The invention also relates to diagnostic kits comprising reagents for determining the presence and/or level of the biomarkers and methods of detecting or diagnosing colorectal cancer. | 12-26-2013 |
Patent application number | Description | Published |
20080209120 | Accelerating cache performance by active cache validation - Described is a technology by which a web proxy server evaluates its cached objects, and when an object is invalid, performs a freshness check on that object, independent of any client requests. As a result, the cache contains objects that have a greater likelihood of being fresh when requested by a client. By scanning a web cache data structure to determine whether corresponding cached content is still valid, and sending a freshness check to a web server when the content is not valid, the cache is kept up to date. The scanning may be periodic or based upon some other triggering event, and all of the cache's corresponding entries may be scanned, or some smaller subset of the entries. In one example implementation, a web proxy server that contains the cache includes a freshness check mechanism that scans and keeps the cached objects up to date. | 08-28-2008 |
20090094263 | ENHANCED UTILIZATION OF NETWORK BANDWIDTH FOR TRANSMISSION OF STRUCTURED DATA - Systems and methods are described that improve the efficiency of byte caching mechanisms when transmitting or receiving structured data. Some of these techniques may normalize the structured data before transmission over the network. Other techniques may use templates or semantic differences. | 04-09-2009 |
20100218247 | SERVICE ACCESS USING A SERVICE ADDRESS - A method is disclosed that includes assigning a service address to a service of a private network. The service of the private network is accessible, via a gateway, by a client computer. The method also includes turning off duplicate address detection at the gateway. The gateway is associated with a public network address that is different from the service address. | 08-26-2010 |
20100218248 | REDIRECTION OF SECURE DATA CONNECTION REQUESTS - Methods, systems, and computer-readable media are disclosed for processing a secure data connection request. A particular method receives, at a first gateway, a secure data connection request from a client identifying a server to connect to. The first gateway sends the client device a redirect message instructing the client device to attempt alternate connection via a second gateway. The client sends a secure data connection request to the second gateway and the second gateway facilitates the secure data connection between the client and the server. | 08-26-2010 |
20100228989 | ACCESS CONTROL USING IDENTIFIERS IN LINKS - Methods, systems, and computer-readable media are disclosed for access control. A particular method receives a resource access identifier associated with a shared computing resource and embeds the resource access identifier into a link to the shared resource. The link to the shared resource is inserted into an information element. An access control scheme is associated with the information element to generate a protected information element, and the protected information element is sent to a destination computing device. | 09-09-2010 |
20100263049 | VULNERABILITY DETECTION BASED ON AGGREGATED PRIMITIVES - Methods, systems, and computer-readable media are disclosed for detecting vulnerabilities based on aggregated primitives. A particular method includes receiving a plurality of data transmissions. At least one of the data transmissions includes a protocol anomaly that is not indicative of a security threat. The method includes identifying a plurality of primitives associated with the data transmissions. The primitives are aggregated, and an attack condition is identified based on the aggregated primitives. A security alert is generated based on the identified attack condition. | 10-14-2010 |